Non-Hodgkin Lymphoma

Criteria to qualify for study: Drug used in study:
  • B-Cell NHL, CLL-SLL, Waldenstrom’s Macroglobulinemia, Richter’s transformation, Follicular Lymphoma, MCL, MZL

HR 52

A Phase 1 Dose Escalation Study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ARQ 531 in selected subjects with Relapsed or Refractory Hematologic Malignancies.

HR 52 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

HR 56 TTI-622-01 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory multiple myeloma or relapsed of refractory B-Cell NHL after at least 2 prior regimens.

HR 59

A phase 1a/1b open label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed of refractory B-Cell Non Hodgkin Lymphoma.

HR 59 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Confirmed NHL, iNHL, or ALL; evidence of CD19 expression.

HR 62

A Phase 1/2 Open-Label, Clinical Trial of TC-110 T Cells in adults with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia.

HR 62 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • ECOG<3, LVET, >50%

HR 64

A phase 1, open label, multicenter, dose escalation study of PRT1419 in subjects with relapsed/refractory hematological malignancies.

HR 64 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • At least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody.

LYM 151

A Single-Arm, open –label phase ½ study evaluating the safety and efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR-T Cell Therapy in patients with relapsed/refractory Large B-Cell and Follicular Lymphoma.

LYM 151 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • ECOG <=2; diagnosis of classical Hodgkin Lymphoma

LMY 157

A Phase 2 front line PET-CT 2 response adapted Brentuximab Vedotin and Nivolumab incorporated and radiation free management of early stage classical Hodgkin Lymphoma (cHL)

LMY 157 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • FL, MZL, SLL, DLBCL, HGBCL, PMBCL, MCL, or CLL; ECOG 0 or 1

LYM 166

Safety and efficacy of GEN3009 (DuoHexaBody-CD37) in relapsed or refractory B-cell Non-Hodgkin Lymphoma – A first in human, Open label, Phase 1/lla dose escalation trial with dose expansion cohorts.

LMY 166 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Relapsed/refractory Large B-cell Lymphoma; at least 1 measurable lesion; at least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody

LYM 168

A Single-Arm, Open-Label, Phase 1/2 study evaluating the safety, efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR-T Cell Therapy in subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

LMY 168 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • CD20+; relapsed of refractory following anti – CD20 monoclonal antibody

LYM 171

A Phase 1/2, open label, dose escalation trial of GEN3013 in patients with relapsed, progressive or refractory B Cell Lymphoma.

LMY 171 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R CLL, SLL, WM, MCL, MZL, FL or DLBCL; ECOG 0 or 1

LYM 184

A Phase 1 dose escalation, safety and tolerability study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) degrader, in adults with relapsed/refractory B-Cell malignancies.

LMY 184 Clinical Trial